SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2001
Neurocrine Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-28150 33-0525145
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction of Incorporation) Identification No.)
10555 Science Center Drive, San Diego, California 92121
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (858) 658-7600
This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a
Delaware corporation (the "Company"), in connection with the matters described
herein.
Item 5. Other Events.
On November 16, 2001, the Company announced that it has initiated the first
pivotal Phase III clinical trial of NBI-34060 in approximately 500 patients with
chronic (primary) insomnia. A copy of the Company's press release announcing the
initiation of the clinical trial, dated November 16, 2001, is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
Item 7. Exhibits.
(c) Exhibits.
Exhibit
Number Description of Exhibit
------ ----------------------
99.1 Press Release, dated November 16, 2001.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 16, 2001 NEUROCRINE BIOSCIENCES, Inc.
By: /s/ PAUL W. HAWRAN
--------------------------
Paul W. Hawran
Senior Vice President and
Chief Financial Officer